Co-Diagnostics (LTS:0A50) Cyclically Adjusted FCF per Share: $-3.86 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A50 Co-Diagnostics Inc LTS:0A50
63 GF Score
Price $1.52
GF Value $2.17
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Cyclically Adjusted FCF per Share?

Co-Diagnostics LTS:0A50 -1.94% 63 Cyclically Adjusted FCF per Share is $-3.86 as of Mar. 2026. GuruFocus rates LTS:0A50 with a GF Score™ of 63/100 and a GF Value™ of $2.17 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Co-Diagnostics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-3.545. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-3.86 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-03), Co-Diagnostics's current stock price is $1.52. Co-Diagnostics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-3.86. Co-Diagnostics's Cyclically Adjusted Price-to-FCF of today is .


Co-Diagnostics  (LTS:0A50) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Co-Diagnostics Cyclically Adjusted FCF per Share Related Terms


Co-Diagnostics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Cyclically Adjusted FCF per Share Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -3.57

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -3.13 -3.57 -3.86

LTS:0A50 vs HSCS, NVNO, SINT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Co-Diagnostics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Cyclically Adjusted Price-to-FCF falls into.


LTS:0A50
63GF Score
Co-Diagnostics Inc LTS:0A50
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Co-Diagnostics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-3.545/330.2130*330.2130
=-3.545

Current CPI (Mar. 2026) = 330.2130.

Co-Diagnostics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.552 241.018 -0.756
201609 -0.799 241.428 -1.093
201612 -1.491 241.432 -2.039
201703 -1.236 243.801 -1.674
201706 -0.791 244.955 -1.066
201709 -3.964 246.819 -5.303
201712 -2.512 246.524 -3.365
201803 -2.382 249.554 -3.152
201806 -2.355 251.989 -3.086
201809 -2.861 252.439 -3.742
201812 -2.326 251.233 -3.057
201903 -2.554 254.202 -3.318
201906 -2.344 256.143 -3.022
201909 -2.102 256.759 -2.703
201912 -2.915 256.974 -3.746
202003 -1.887 258.115 -2.414
202006 0.907 257.797 1.162
202009 8.567 260.280 10.869
202012 20.071 260.474 25.445
202103 12.130 264.877 15.122
202106 12.293 271.696 14.941
202109 11.366 274.310 13.682
202112 4.756 278.802 5.633
202203 6.404 287.504 7.355
202206 1.059 296.311 1.180
202209 0.851 296.808 0.947
202212 -4.364 296.797 -4.855
202303 -6.203 301.836 -6.786
202306 -6.294 305.109 -6.812
202309 -6.131 307.789 -6.578
202312 -5.340 306.746 -5.749
202403 -8.937 312.332 -9.449
202406 -5.282 314.175 -5.552
202409 -7.287 315.301 -7.632
202412 -8.070 315.605 -8.444
202503 -8.274 319.799 -8.543
202506 -7.870 322.561 -8.057
202509 -4.735 324.800 -4.814
202512 -3.360 324.054 -3.424
202603 -3.545 330.213 -3.545

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-3.86 mean?
Co-Diagnostics (LTS:0A50) has a Cyclically Adjusted FCF per Share of $-3.86 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Co-Diagnostics and its competitors.
Is Co-Diagnostics' Cyclically Adjusted FCF per Share too high?
Co-Diagnostics' current Cyclically Adjusted FCF per Share is $-3.86. Overall, Co-Diagnostics has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Cyclically Adjusted FCF per Share compare to HSCS and NVNO?
Co-Diagnostics' Cyclically Adjusted FCF per Share of $-3.86 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current Cyclically Adjusted FCF per Share is $-3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Co-Diagnostics (LTS:0A50) is currently considered Possible Value Trap. The stock's GF Value™ is $2.17, compared to a current price of $1.52 — trading 30% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-3.86. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Co-Diagnostics (LTS:0A50), the current Cyclically Adjusted FCF per Share is $-3.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (LTS:0A50) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued. The current stock price of $1.52 is trading 30% below its estimated GF Value™ of $2.17. GuruFocus considers Co-Diagnostics to be Possible Value Trap.

Key valuation signals for LTS:0A50:

  • Cyclically Adjusted FCF per Share: $-3.86
  • GF Value™: $2.17 vs. price of $1.52 (30% below fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the LTS:0A50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Co-Diagnostics Business Description

Other Exchanges CODX:USA
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for LTS:0A50

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.52
Price
$2.17
GF Value